Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer

Xu Peng; Isaac Woodhouse; Gemma Hancock; Robert Parker; Kristina Marx; Julius Müller; Silvia Salatino; Thomas Partridge; Annalisa Nicastri; Hanqing Liao; Gary Kruppa; Karin Hellner; Lucy Dorrell; Nicola Ternette

iScience (Mar 2023)

Novel canonical and non-canonical viral antigens extend current targets for immunotherapy of HPV-driven cervical cancer

Xu Peng,
Isaac Woodhouse,
Gemma Hancock,
Robert Parker,
Kristina Marx,
Julius Müller,
Silvia Salatino,
Thomas Partridge,
Annalisa Nicastri,
Hanqing Liao,
Gary Kruppa,
Karin Hellner,
Lucy Dorrell,
Nicola Ternette

Affiliations

Xu Peng: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK
Isaac Woodhouse: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK
Gemma Hancock: Nuffield Department of Medicine, University of Oxford, OX3 7FZ Oxford, UK
Robert Parker: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK; The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK
Kristina Marx: Bruker Daltonics, Fahrenheitstraße 4, 28359 Bremen, Germany
Julius Müller: The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK
Silvia Salatino: Wellcome Centre Human Genetics, University of Oxford, OX3 7BN Oxford, UK
Thomas Partridge: Nuffield Department of Medicine, University of Oxford, OX3 7FZ Oxford, UK
Annalisa Nicastri: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK; The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK
Hanqing Liao: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK; The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK
Gary Kruppa: Bruker Daltonics, Fahrenheitstraße 4, 28359 Bremen, Germany
Karin Hellner: Nuffield Department of Women’s and Reproductive Health, University of Oxford, John Radcliffe Hospital, OX3 9DU Oxford, UK
Lucy Dorrell: Nuffield Department of Medicine, University of Oxford, OX3 7FZ Oxford, UK; The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK; Immunocore Ltd., OX14 4RY Abingdon, UK
Nicola Ternette: Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, OX3 7DQ Oxford, UK; The Jenner Institute, University of Oxford, OX3 7DQ Oxford, UK; Corresponding author

Journal volume & issue: Vol. 26, no. 3
p. 106101

Abstract

Read online

Summary: Current immunotherapeutic approaches for human papillomavirus (HPV)-driven cervical cancer target the viral oncogenes E6 and E7. We report viral canonical and alternative reading frame (ARF)-derived sequences presented on cervical tumor cells, including antigens encoded by the conserved viral gene E1. We confirm immunogenicity of the identified viral peptides in HPV-positive women, and women with cervical intraepithelial neoplasia. We observe consistent transcription of the E1, E6, and E7 genes in 10 primary cervical tumor resections from the four most common high-risk HPV subtypes (HPV16, 18, 31, and 45), suggesting the suitability of E1 as therapeutic target. We finally confirm HLA presentation of canonical peptides derived from E6 and E7, and ARF-derived viral peptides from a reverse-strand transcript spanning the HPV E1 and E2 genes in primary human cervical tumor tissue. Our results extend currently known viral immunotherapeutic targets in cervical cancer and highlight E1 as an important cervical cancer antigen.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords